Podcasts

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the significance of the FDA approval of daratumumab plus VRd for the treatment of newly diagnosed, transplant-ineligible multiple myeloma.

Eric K. Singhi, MD, discusses where TROP2-directed ADCs like datopotamab deruxtecan and sacituzumab tirumotecan may fit in evolving treatment algorithms in lung cancer.

Drs Camidge and Clackson discussed Dr Clackson’s career journey through the biotechnology field, which began with a curiosity about biology and evolution.

Anne Chiang, MD, PhD, discusses the rapidly evolving treatment landscape in SCLC and what this new era of innovation means for patients.

Drs Kruse and O’Brien highlight the various roles of imaging modalities in breast cancer diagnosis and treatment decision-making.

David Carbone, MD, PhD, discusses the 6-year data from the phase 3 CheckMate 9LA trial (NCT03215706).

Rashmi Chugh, MD, discusses the ongoing development of the investigational γ-secretase inhibitor varegacestat for patients with desmoid tumors.

Drs Matulonis and Campos discuss the evolving landscape of newly diagnosed cervical cancer, from epidemiologic trends to emerging therapeutic strategies.

Rachna T. Shroff, MD, MS, FASCO, and Kristen Spencer, DO, discuss factors weighed when navigating first-line chemotherapy selection in pancreatic cancer.

Drs Armstrong and Tawagi highlight anticipated data from the upcoming 2026 Genitourinary Cancers Symposium in prostate, bladder, and kidney cancers.

Girindra Raval, MD, and Hossein Borghaei, DO, MS, discuss Borghaei’s personal journey into medicine and oncology.

Philippos Costa, MD, and Hari Deshpande, MD, answer common questions about chondrosarcoma staging, diagnosis, surgery, and future research avenues.

Alexander I. Spira, MD, PhD, FACP, FASCO, discusses the FDA approval of subcutaneous amivantamab for patients with EGFR-mutated NSCLC.

Drs Camidge and Kantor reflect on Dr Kantor's decades-long career in oncology, which was propelled by a devotion to patients.

Nicholas Short, MD, discusses TKIs like ponatinib and combining them with other treatments for ALL.

Christopher Lieu, MD, expands on current treatment strategies and factors informing third-line sequencing decisions in mCRC.

Dr Bardia discusses key findings from the phase 3 lidERA Breast Cancer study of giredestrant in estrogen receptor–positive, HER2-negative breast cancer.

Dr Schrag weighed in on where oncology stands today and previewed the goals she hopes to advance during her tenure as ASCO President in 2027-2028.

Drs Whitman and Patel discuss the evolving treatment paradigm for patients with CSCC, emphasizing the role of neoadjuvant and adjuvant immunotherapies.

Dr Jhaveri discusses the evaluation of sacituzumab govitecan earlier in the HR-positive, HER2-negative metastatic breast cancer treatment paradigm.

Andrew Lipsky, MD, discusses data with pirtobrutinib in relapsed/refractory CLL and the effect of its FDA approval on sequencing decisions for this disease.